• Mohammed Dheyaa Marsool Marsool, Neel Vora, Ali Dheyaa Marsool Marsool, Shefali Pati, Manasi Narreddy, Parth Patel, Srikanth Gadam, and Priyadarshi Prajjwal.
• University of Baghdad/Al-Kindy College of Medicine, Baghdad, Iraq.
• Dis Mon. 2023 Nov 1; 69 (11): 101606101606.

AbstractThe prevalence and incidence of Ulcerative Colitis (UC), a recurrent and remitting inflammatory condition, are rising. Any part of the colon may be affected, beginning with inflammation of the mucosa in the rectum and continuing proximally continuously. Bloody diarrhea, tenesmus, fecal urgency, and stomach pain are typical presenting symptoms. Many patients present with extraintestinal manifestations (EIMs) including musculoskeletal, ocular, renal, hepatobiliary, and dermatological presentation, among others. Most cases are treated with pharmacological therapy including mesalazine and glucocorticoids. Fecal microbiota transplantation (FMT) is a novel procedure that is increasingly being used to treat UC, however, its use yet remains controversial because of uncertain efficacy. FMT can lower gut permeability and consequently disease severity by boosting short-chain fatty acids production, helping in epithelial barrier integrity preservation. Upadacitinib (JAK Kinase inhibitor) is another newer treatment option, which is an FDA-approved drug that is being used to treat UC. This review article provides a comprehensive review of the EIMs of UC, the role of FMT along with various recent clinical trials pertaining to FMT as well as other diagnostic and therapeutic updates.Copyright © 2023 Elsevier Inc. All rights reserved.

16 keywords...

hide…